Flexion Therapeutics Inc (NASDAQ:FLXN) insider Michael D. Clayman purchased 4,046 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were bought at an average cost of $12.36 per share, with a total value of $50,008.56. Following the completion of the acquisition, the insider now owns 70,856 shares of the company’s stock, valued at $875,780.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Michael D. Clayman also recently made the following trade(s):
- On Thursday, January 3rd, Michael D. Clayman sold 3,278 shares of Flexion Therapeutics stock. The stock was sold at an average price of $12.36, for a total value of $40,516.08.
Flexion Therapeutics stock traded down $0.09 during midday trading on Thursday, reaching $12.15. The company’s stock had a trading volume of 18,391 shares, compared to its average volume of 514,170. Flexion Therapeutics Inc has a fifty-two week low of $10.98 and a fifty-two week high of $29.10. The company has a debt-to-equity ratio of 1.35, a quick ratio of 7.58 and a current ratio of 7.78. The company has a market cap of $465.00 million, a P/E ratio of -2.73 and a beta of 1.70.
Several large investors have recently added to or reduced their stakes in FLXN. Point72 Asset Management L.P. purchased a new stake in Flexion Therapeutics in the 3rd quarter valued at about $23,768,000. Capital International Investors bought a new stake in shares of Flexion Therapeutics in the 3rd quarter valued at approximately $12,162,000. D. E. Shaw & Co. Inc. increased its holdings in shares of Flexion Therapeutics by 516.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 250,402 shares of the specialty pharmaceutical company’s stock valued at $2,835,000 after acquiring an additional 209,809 shares during the last quarter. Clearline Capital LP increased its holdings in shares of Flexion Therapeutics by 86.8% in the 3rd quarter. Clearline Capital LP now owns 391,076 shares of the specialty pharmaceutical company’s stock valued at $7,317,000 after acquiring an additional 181,736 shares during the last quarter. Finally, Wasatch Advisors Inc. increased its holdings in shares of Flexion Therapeutics by 27.8% in the 3rd quarter. Wasatch Advisors Inc. now owns 828,224 shares of the specialty pharmaceutical company’s stock valued at $15,496,000 after acquiring an additional 180,293 shares during the last quarter. 95.12% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts recently weighed in on FLXN shares. Zacks Investment Research raised Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Thursday, December 6th. Wells Fargo & Co set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a report on Sunday, December 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 price target (down from $42.00) on shares of Flexion Therapeutics in a report on Friday, January 4th. ValuEngine raised Flexion Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 16th. Finally, Northland Securities reissued a “buy” rating and issued a $20.00 target price on shares of Flexion Therapeutics in a report on Friday, March 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $23.42.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2019/03/14/insider-buying-flexion-therapeutics-inc-flxn-insider-purchases-4046-shares-of-stock.html.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.